Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
THX PharmaFRA:3VG -3.15%31 EV-to-OCF is -65.74 as of Aug. 16, 2026. GuruFocus rates FRA:3VG with a GF Score™ of 31/100. The stock has 1 warning sign investors should review. Among 1,411 Biotechnology companies, THX Pharma ranks better than 94.12% on this metric.
EV-to-OCF is calculated as enterprise value divided by its cash flow from operations. As of today, THX Pharma's Enterprise Value is €54.04 Mil.
THX Pharma's Cash Flow from Operations for the trailing twelve months (TTM) ended in Dec. 2025 was €-0.82 Mil. Therefore, THX Pharma's EV-to-OCF for today is -65.74.
The historical rank and industry rank for THX Pharma's EV-to-OCF or its related term are showing as below:
FRA:3VG'
s EV-to-OCF Range Over the Past 10 Years
Min: -65.74 Med: 0 Max: -65.74
Current: -65.74
During the past 11 years, the highest EV-to-OCF of THX Pharma was -65.74. The lowest was -65.74. And the median was .
FRA:3VG's EV-to-OCF is ranked better than 94.12% of 1411
companies
in the Biotechnology industry
Industry Median: -3.63
vs FRA:3VG: -65.74
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
THX Pharma's share price for today is €4.15.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. THX Pharma's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was €-0.252.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
THX Pharma EV-to-OCF Related Terms
THX Pharma EV-to-OCF Historical Data
* Premium members only.
The historical data trend for THX Pharma's EV-to-OCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, THX Pharma's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
THX Pharma EV-to-OCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, THX Pharma's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where THX Pharma's EV-to-OCF falls into.
THX Pharma's current Enterprise Value is €54.04 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. THX Pharma's Cash Flow from Operations for the trailing twelve months (TTM) ended in Dec. 2025 was €-0.82 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
THX Pharma (FRA:3VG) has a EV-to-OCF of -65.74 as of Aug. 16, 2026. According to the industry distribution chart, THX Pharma ranks #83 out of 1411 companies in the Biotechnology industry, placing it in the top 5.9%.
Is THX Pharma's EV-to-OCF too high?
THX Pharma's current EV-to-OCF is -65.74. Based on the distribution chart, THX Pharma ranks #83 out of 1411 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, THX Pharma has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does THX Pharma's EV-to-OCF compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, THX Pharma ranks #83 out of 1411 companies for EV-to-OCF. This places THX Pharma in the top 6% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Biotechnology company?
A good EV-to-OCF depends on the Biotechnology industry context. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. THX Pharma's current EV-to-OCF is -65.74. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is THX Pharma stock overvalued right now?
THX Pharma (FRA:3VG) has a current EV-to-OCF of -65.74. The current EV-to-OCF is -65.74. THX Pharma's overall GF Score™ is 31/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For THX Pharma (FRA:3VG), the current EV-to-OCF is -65.74 as of Aug. 16, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
THX Pharma Formerly Theranexus SA is a France based biopharmaceutical company. It is engaged in developing drug candidates to be used in the treatment of central nervous system (CNS) disorders. The company's therapeutics platform is based on simultaneously targeting neurons and glial cells by creating and developing innovative combinations of two distinct drugs: a CNS drug targeting neuronal activity; and a drug targeting glial cells. The drug candidates of the organization are THN102 to treat excessive daytime sleepiness in Parkinson's disease, THN201 for the treatment of neurocognitive disorders in Alzheimer's disease and THN101 for neuropathic pain.
31GF Score
Get the complete analysis for FRA:3VG
EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:3VG has been successfully added to your 
